Managing Malignant Diseases with Imutrex (Methotrexate)

Imutrex (Methotrexate) 25mg tablets, an essential cytotoxic
antimetabolite, play a pivotal role in combating malignant tissue with high
cell turnover By irreversibly binding with dihydrofolate reductase and
inhibiting nucleic acid synthesis, Imutrex effectively hinders cell division
While it targets malignant cells, it may adversely affect other rapidly
dividing normal tissues, necessitating careful consideration of its usage

 Description IMUTREX TABLETS

IMUTREX TABLETS mode of action revolves around its function as a
folic acid antagonist, leading to a deficiency that hinders nucleic acid
synthesis Rapidly absorbed and predominantly excreted through the kidneys, its
effectiveness depends on factors such as renal function and the dose
administered This potent medication finds utility in managing various malignant
diseases, including acute lymphoblastic leukemia, choriocarcinoma, and
psoriasis

 Indications and Contraindications

IMUTREX TABLETS is particularly effective in the treatment of
lymphosarcoma, Burkitt’s lymphoma, osteogenic sarcoma, and tumors in various
organs However, it is contraindicated in pregnant women, those with poor
nutrition, serious renal or liver disorders, and individuals with bone marrow
hypoplasia or blood-related issues Close monitoring and regular blood counts
are crucial during Imutrex therapy, and adjustments to the dosage may be
necessary based on observed toxicity

 Undesirable Effects and Precautions

Patients undergoing Imutrex therapy may experience a range
of adverse effects, including gastrointestinal disturbances, bone marrow
depression, and an increased susceptibility to long bone fractures Regular
hematological assessments and close vigilance for signs of toxicity are
imperative Caution is advised for patients with impaired renal function,
infections, peptic ulcers, or debility Dosage adjustments should be made
accordingly to mitigate the potential risks associated with its usage

 Dosage Guidelines IMUTREX TABLETS

For acute lymphoblastic leukemia, the recommended oral
dosage is 33 mg of Imutrex per M2 of body surface daily, in combination with
prednisolone The maintenance dosage for achieving remission is typically 20-30
mg/M2 of body surface orally twice a week In the case of Mycosis Fungoides, the
dosage may range from 25 to 10 mg orally daily for several weeks or months,
with appropriate adjustments as necessary

 Given the potential risks and benefits, the usage of Imutrex
necessitates close medical supervision and careful consideration of the
patient’s overall healthcare and condition